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Identity 
Other names: FA, FA1, FAA, FACA, FA-H, FAH, 
FANCH 




43 exons spanning 80 kb with 4365 bp open reading 
frame (Lo Ten Foe et al., 1996).  
The 5-prime region upstream of the putative 
transcription start site of FANCA has a GC-rich region 
instead of TATA or CAAT boxes, which is typical of 
housekeeping genes (Ianzano et al., 1997).  
Numerous Alu repeats are present in the FANCA gene, 
suggesting that Alu-mediated recombination may be an 
important mechanism for the generation of Fanconi 
anemia-producing mutations. 
Transcription 
Multiple transcrips have been described and two types 
produces proteins; a 5,5 kb mRNA corresponding to 
NM_000135.2 (5460 bp) and NM_001018112 (1673 





Figure 1. Genomic contex of FANCA gene in chromosome 16. Image adapted from NCBI. 
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Two isoforms with accession number in UniProt; the 
canonical sequence NP_000126.2 (1455 aa) and 
NP_001018122.1 (297 aa). 
Description 
1455 amino acids (163 kDa) conserved in lower 
vertebrates including zebrafish with 2 nuclear 
localisation signals (NLS) consensus sequences in N-
terminus (Lightfoot et al., 1999), putative peroxidase 
domain (Ren and Youssoufian, 2001) and a partial 
leucine zipper in 1069-1090 (Lo Ten Foe et al., 1996), 
none proven to be functional as such. Despite FANCA 
protein lack of sequence homologies or motifs that can
be assigned to a molecular function, many interactions 
with other proteins have been described. In this sense, 
FANCA has a FANCG-binding domain overlapping 
with NLS region (Waisfisz et al., 1999), a region of 
interaction with the protein FAAP20 between residues 
1095 and 1200 (Ali et al., 2012) or for interaction with 
BRCA1 through the central part of FANCA protein (aa 
740-1083) (Folias et al., 2002). 
Through different complexes FANCA can interact with 
other proteins such as alpha spectrin II, SWI/SNF 
complex or BLM (DNA-helicase Bloom protein) and 
other proteins associated with this complex (McMahon 
et al., 1999; Otsuki et al, 2001; Meetei et al., 2003). 
FANCA is normally phosphorylated including 
phosphorylation by ATR-CHK1 on serine 1449 in a 
process that is required for the formation of the nuclear 
complex (Collins et al., 2009). FANCA has a 
consensus sequence for Akt kinase near serine 1149 
and its phosphorylation can act as a negative regulator 
(Otsuki et al., 2002) (Figure 2). 
Expression 
Wide: brain, liver, placenta, testis, tonsils (mRNA); in 
mice: protein expression predominant in lymphoid 
organs, testis, ovary (Van de Vrugt et al., 2000). 
Localisation 
FANCA can be cytoplasmic and nuclear where it exerts 
its primary function. 
Function 
FANCA is one of the15 known FA proteins that 
participate in the FA/BRCA pathway which 
participates in the repair of DNA interstrand cross-
links, probably involving homologous recombination 
and the coordination for other DNA damage repair 
events, including nucleotide excision repair (NER) and 
translesion synthesis (Moldovan and D'Andrea, 2009). 
The FA/BRCA pathway may be divided in three parts; 
1) FA core complex (FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCG, FANCL and FANCM) and 
six associated factors (FAAP100, FAAP24, FAAP20, 
HES1, MHF1 and MHF2), 2) ID complex (FANCD2 
and FANCI) and 3) downstream FA proteins 
(FANCD1/BRCA2, FANCN/PALB2, FANCJ/BRIP1, 
FANCP/SLX4, FANCO/RAD51C) (Moldovan and 
D'Andrea, 2009; Ali et al., 2012) (Figure 3). 
Several subcomplex are formed in the cytoplasm and 
from here FANCB-FANCL-FAAP100 are transported 
together to the nucleus (Ling et al., 2007). FANCA and 
FANCG form a complex in the cytoplasm, through an 
N-term FANCA (involving the nuclear localization 
signal) - FANCG interaction; FANCC join the complex  
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and phosphorylation of FANCA would induce its 
translocation into the nucleus (Garcia-Higuera et al., 
2000; Kruyt et al., 1999). The FA subcomplexes 
translocates into the nucleus, where FANCE and 
FANCF are present; and join to the complex (de Winter 
et al., 2000; kee and D'Andrea, 2010). A large FA core 
complex is generated with FANCM-FAAP24. 
Interstrand cross-links are recognized by the FANCM-
FAAP24-MHF1/2 complex which recruits the rest of 
the FA core proteins by interaction between FANCM 
and FANCF. Because of the ubiquitin E3 ligase activity 
present in FANCL (Hodson et al., 2011) the 
heterodimer ID complex formed by FANCD2 and 
FANCI can be monoubiquitinated and then translocated 
to chromatin, interacting with downstream proteins i  
the FA pathway such as FANCD1/BRCA2, 
FANCN/PALB2, FANCJ/BRIP1, FANCP/SLX4, 
FANCO/RAD51C and with BRCA1 (Garcia-Higuera 
et al., 2001) and the nuclease FAN1 (Liu et al., 2010). 
These downstream FA proteins are involved in DNA 
repair by homologous recombination (Moldovan and 
D'Andrea, 2009). In addition to DNA damage, the FA 
pathway can be activated during S phase of cell cyce.  
After DNA repair, FANCD2 and FANCI return to the 
non-ubiquinated form by the action of a complex 
ubiquitin-specific protease USP1/UAF1 (Nijman et al.,
2005) (Figure 3). 
Biallelic mutations in FANCA (or in any other gene 
encoding proteins of the FA core complex) prevent the 
ubiquitin E3 ligase activity and the monoubiquinitation 
of FANCD2 and FANCI resulting in a defective 
FA/BRCA pathway. 
Homology 
No known complete homology or functional motifs. 
Mutations 
Note 
Epigenetics: Although hypermethylation of the 
promotor of different FA genes (FANCD1/BRCA2, 
FANCB, FANCC, FANCL, FANCN and especially in 
FANCF) has been described in several sporadic 
malignancies this effect has not been described so far in
FANCA (Valeri et al., 2011). 
 
 
Figure 3. Overview of the FA/BRCA pathway. Fanconi proteins are shown in yellow. Other proteins in the FA core complex necessary 
for monoubiquitination of the ID complex are shown in blue (FAAP; fanconi anemia associated protein). Downstream proteins involved in 
the pathway are shown in pink. (ICL: interstrand cross-link). ATR-CHK1 phosphorylates multiple FA and FA-associated proteins including 
FANCA, FANCE, FANCD2, FANCI and BRCA1. Not all protein interactions are shown and proximity nor imply direct interaction (Adapted 
from Valeri et al., 2011). 
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Germinal 
The number of different pathogenic mutations in 
FANCA gene is very high. Mutations are 
heterogeneous; point mutations, splicing mutations, 
large intragene deletions probably Alu-mediated or 
insertions have been described (Morgan et al., 1999; 
Levran et al., 2005). Over 90% of the mutations are 
private, with about 30% being relatively large 
deletions. Founder mutations have been described in 
South Africa and Spanish Gypsies (Tipping et al., 
2001; Callen et al., 2005). Unlike mutations in 
downstream FA genes such as FANCD1/BRCA2 
(breast, ovarian, and solid childhood cancer), 
FANCN/PALB2 (breast cancer) or FANCO/RAD51C 
(breast and ovarian cancer), FANCJ/BRIP1 (breast 
cancer and solid childhood cancer), the carriers of 
monoallelic mutations in FANCA do not seem to have 
a significant risk of cancer (Garcia and Benitez, 2008). 
However, It has been recently described in Finnish 
breast cancer families that FANCA deletions might 
contribute to breast cancer susceptibility, potentially in 
combination with other germline mutations (Solyom et 
al., 2011). 
Somatic 
In FA-A patients, the presence of wild type cells with a 
restored FANCA function, can be obtained via back 
mutation, intragenic crossover, compensating 
deletions/insertions, or gene conversion of either the 
paternal or maternal allele. This can lead to a selective 
advantage of corrected cells generating the so-called 
somatic mosaicism (Gregory et al., 2001; Gross et al., 
2002). The clinical significance of this mosaicism is 
unclear but there are cases that show improvement of 
their hematological status when the correction involves 
hematopoietic stem cells. Somatic mutations and 
epigenetic silencing in some FA genes occur in a 
variety of cancers in the general population (non-FA 
patients) (Valeri et al., 2011). In relation to FANCA, 
deletions or point mutations were found in several 
sporadic AML (Tischkowitz et al., 2004; Condie et al.,
2002). 
Implicated in 
Fanconi anaemia (FA) 
Note 
FANCA is implicated in the FA complementation 
group A (FA-A) that is the most frequent 
complementation group accounting for about 70% of 
FA cases, although geographical variations may alter 
the prevalence in some complementation groups 
(Casado et al., 2007). 
Disease 
Fanconi anaemia is a chromosome instability 
syndrome/cancer prone disease (at risk of leukaemia 
and squamous cell carcinoma), progressive bone  
marrow failure (pancytopenia), and several congenital 
abnormalities mainly: skin hiperpigmentation, skeletal 
malformation, small stature or urogenital abnormalities 
(Auerbach, 2009). 
Prognosis 
Fanconi anaemia's prognosis is poor; mean survival is 
20 years: patients die of bone marrow failure 
(infections, haemorrhages), leukaemia, or solid cancer 
specially squamous carcinomas (SCC) in adult patients. 
Hematopoietic stem cell transplantation with a suitable 
HLA-matched donor is currently the best treatment to 
cure the aplastic anemia or leukaemia (Gluckman and 
Wagner, 2008). 
It has been shown that significant phenotypic 
differences were found between the various 
complementation groups. In FA group A, patients 
homozygous for null mutations had an earlier onset of 
anemia and a higher incidence of leukemia than those 
with mutations producing an altered protein. Patients 
homozygous for null mutations in FANCA are high-
risk groups with a poor hematologic outcome and 
should be considered as candidates both for frequent 
monitoring and early therapeutic intervention (Faivre et 
al., 2000). However, in another recent study, no clinical 
differences in terms of onset of hematologic disease 
and number of congenital anomalies were found in 
patients with expression of a mutant form of FANCA 
protein compared with patients without expression of 
the protein (Castella et al., 2011). 
Cytogenetics 
Compared to control cells, an increase of chromatid-
type aberrations (breaks, gaps, interchanges; increased 
rate of breaks) is observed in FA cells when samples 
are treated with specific clastogens known as DNA 
inter-strand cross-linking agents (e.g. mitomycin C, 
diepoxybutane). Theses agents are widely used for FA 
diagnosis (Auerbach, 1993). 
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